Drug Profile
MCLA 145
Alternative Names: CD137 x PD-L1 Biclonics®; MCLA-145Latest Information Update: 03 Mar 2023
Price :
$50
*
At a glance
- Originator Merus
- Developer Incyte Corporation; Merus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 03 Mar 2023 Phase-I clinical trials in Solid tumours (Combination therapy) (IV)
- 03 Nov 2022 Clinical trials in Solid tumours (Combination therapy) (IV)
- 08 Aug 2022 MCLA 145 is still in phase-I development stage in Solid-tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, USA and Netherlands (IV, Infusion) (NCT03922204)